NCT02457273 - Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2015

Primary Completion Date

April 18, 2018

Study Completion Date

December 1, 2018

Conditions

Neuroendocrine Carcinomas

Interventions

DRUG

TLC 388

40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.

Trial Locations (7)

100

National Taiwan University Hospital, Taipei

407

Taichung Veterans General Hospital, Taichung

Unknown

Chung Gung Memorial Hospital(Kaohsiung City), Kaohsiung City

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Chang Gung Memorial Hospital (Lin-Kou),, Linkou District

National Cheng-Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

All Listed Sponsors

collaborator

National Taiwan University Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Taichung Veterans General Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER